Deep vein thrombosis DVT is a serious vascular condition characterized by the formation of blood clots within the deep veins, most commonly in the lower limbs. It can lead to pulmonary embolism PE and post thrombotic syndrome, which increase morbidity, mortality, and healthcare costs. Critically ill patients are at particularly high risk of DVT due to prolonged immobility, multiple organ dysfunction, and hypercoagulability. This study focuses on DVT prevention among critically ill adult patien
Conditions
Interventions
The intervention consists of implementing an evidence-based deep vein thrombosis DVT clinical practice guideline for critically ill adult patients in intensive care units. The guideline includes a str
s clinical judgement.
Experimental Other,Active Comparator Other
DVT CPGs intervention ,Usual care
Sponsors
Suranaree University of Technology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion Criteria 1. Adult patients aged 18 years or older. 2. Admitted to an intensive care unit and expected to stay for at least 48 hours. 3. Classified as critically ill based on clinical assessment and requiring intensive monitoring or life support. 4. Having a risk of developing deep vein thrombosis as identified by physician or nurse using clinical risk assessment. 5. Able to receive care according to the study protocol without contraindication to DVT prophylaxis. 6. Provided written informed consent by the patient or legally authorized representative prior to participation.
Exclusion criteria
Exclusion criteria: 1. Active major bleeding at the time of enrollment. 2. Platelet count less than 30000 per microliter or other coagulation disorders contraindicating prophylaxis. 3. Known contraindication to pharmacologic or mechanical thromboprophylaxis as determined by the attending physician. 4. Current therapeutic anticoagulation for existing venous thromboembolism. 5. Diagnosed deep vein thrombosis or pulmonary embolism before study enrollment. 6. Pregnancy or within six weeks postpartum. 7. Anticipated death or withdrawal of life sustaining treatment within 24 hours after ICU admission. 8. Participation in another interventional clinical trial within the past 30 days. 9. Refusal or withdrawal of consent by the patient or legally authorized representative.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| D-dimer level after intervention ends unit,Vein velocity after intervention ends cm/s | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of Stay on Discharge date days,Deep vein trombosis risk after intervention ends risk score | — |
Countries
Thailand
Contacts
Public ContactChantira Chiaranai
Suranaree University of Technology
Outcome results
None listed